TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / CytoVale Stock

CytoVale Stock

www.cytovale.com/Healthcare / Healthcare providers & servicesFounded: 2013

CytoVale is a biotechnology research company that uses early detection strategies for auto-immune diseases. The company has a mission of using diagnostic interventions to create faster, easier-to-implement medical treatment for patients. Other features of CytoVale are microfluidics and biophysical machine learning. CytoVale was founded by Ajay Shah and Dino Di Carlo in 2013 and is headquartered in San Francisco, CA.

Buy or sell CytoVale stockLearn more about CytoVale IPO

Register To Buy and Sell Shares

For more details on financing and valuation for CytoVale, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access CytoVale’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like CytoVale.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

CytoVale investors also invested in these private companies

Norwest Venture Partners
Western Technology Investment
National Science Foundation
Grids Capital
Baidu Ventures
Google for Startups Accelerator
National Institutes of Health
Sands Capital
Dolby Family Ventures
Breakout Ventures
U.S. Department of Health and Human Services
Global Health Investment Fund
Kayyak Ventures
Pathway Bioventures
Biomedical Advanced Research and Development Authority
Blackhorn Ventures
Pactolus Ventures
Farmore Capital Group
Breakout Labs
NetScientific

Team

Management Team

Ajay Shah Ph.D
Co-Founder & Chief Executive Officer
Bill Blackledge
Chief Financial Officer
Henry Tse Ph.D
Co-Founder & Chief Technology Officer
Robert Scoggins Ph.D
Chief Medical Officer
Dino Di Carlo Ph.D
Co-Founder & Scientific Advisor

Board Members

David Dolby
Dolby Family Ventures
Jack Fuchs
Blackhorn Ventures
Jordanna Schutz
Pactolus Ventures
Lindy Fishburne
Breakout Labs
Pascal Levensohn
Dolby Family Ventures

Frequently Asked Questions About CytoVale’s Stock

plusminus
Can you buy CytoVale’s stock?
CytoVale is not publicly traded on NYSE or NASDAQ in the U.S. To buy CytoVale’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell CytoVale’s stock?
Yes, you can sell stock of a private company like CytoVale. Forge can help you sell your CytoVale stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is CytoVale’s stock price?
CytoVale is a privately held company and therefore does not have a public stock price. However, you may access CytoVale’s private market stock price with Forge Data.
plusminus
What is CytoVale’s stock ticker symbol?
CytoVale does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like CytoVale in the Healthcare providers & services sector

Mark Cuban Cost Plus Drug Company

Sector
Healthcare / Healthcare providers & services
 
 

Solv Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$399.84MM

SWORD Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$1.81B

HeartFlow

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$1.65B

VillageMD

Sector
Healthcare / Healthcare providers & services
 
 

Capsule

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$458.12MM

SnapNurse

Sector
Healthcare / Healthcare providers & services
 
 

Dandy

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$10.41MM

Collective Health

Sector
Healthcare / Healthcare providers & services
Last Round Est. Valuation
$281.98MM

News Highlights

Fierce Biotech 11/16/2023
Cytovale collects $84M to roll out its rapid ER sepsis diagnostic test
After recently launching its emergency room-focused diagnostic for catching early cases of sepsis, Cytovale has raised $84 million in venture capital funding to bolster the system’s rollout. According to the San Francisco-based company, sepsis contributes to more than one-third of all in-hospital deaths—more than 350,000 annually in the U.S.—with about 80% of patients with the bloodstream condition spending at least some time in the ER.
Medical Device Network 01/19/2023
Cytovale’s test gets FDA 510(k) clearance for early sepsis detection
Medical diagnostics company Cytovale has secured 510(k) clearance from the US Food and Drug Administration (FDA) for IntelliSep, its test for the early detection of sepsis. IntelliSep has been designed to help clinicians recognise sepsis and make time-sensitive critical decisions. It provides test results within ten minutes. It is claimed to be the first FDA-approved diagnostic tool for evaluating cellular host response to help identify patients with sepsis in emergency departments.

Trending Companies

Frequently Asked Questions

Updated on: Apr 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.